Top

European Radiology

Published in:

01-12-2012 | Breast

Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy

Authors: Katrin Hegenscheid, Carsten O. Schmidt, Rebecca Seipel, René Laqua, Ralf Ohlinger, Norbert Hosten, Ralf Puls

Published in: European Radiology | Issue 12/2012

Abstract

Objectives

To investigate effects of menopausal status, oral contraceptives (OC), and postmenopausal hormone therapy (HT) on normal breast parenchymal contrast enhancement (CE) and non-mass-like enhancing areas in magnetic resonance mammography (MRM).

Methods

A total of 459 female volunteers (mean age 49.1 ± 12.5 years) underwent T1-weighted 3D MRM 1–5 min after bolus injection of gadobutrol. Quantitative analysis was performed in normal breast parenchyma by manually tracing regions of interest and calculating percentage CE. Semiquantitative analysis was performed in non-mass-like enhancing areas, and signal intensity changes were characterised by five predefined kinetic curve types. The influence of OC (n = 69) and HT (n = 24) on CE was studied using random effects models.

Results

Breast parenchymal enhancement was significantly higher in premenopausal than in postmenopausal women (P < 0.001). CE decreased significantly with the use of OC (P = 0.01), while HT had negligible effects (P = 0.52). Prevalence of kinetic curve types of non-mass-like enhancement differed strongly between pre- and postmenopausal women (P < 0.0001), but was similar in OC users and non-OC users (P = 0.61) as well as HT users and non-HT users (P = 0.77).

Conclusions

Normal breast parenchymal enhancement and non-mass-like enhancing areas were strongly affected by menopausal status, while they were not affected by HT use and only moderately by OC use.

Key Points

• Breast parenchymal enhancement at MR mammography is stronger in premenopausal than postmenopausal women.

• The prevalence of strong enhancing non-mass-like areas is greater before menopause.

• Such enhancing non-mass-like areas may impair lesion detection in premenopausal women.

• Breast parenchymal enhancement is only marginally affected by hormone use.

• Discontinuation of hormone use before MR mammography may be unnecessary.

Hauth EAM, Jaeger H, Maderwald S et al (2006) Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography. Eur Radiol 16:2834–2841PubMedCrossRef

Kuhl CK, Bieling HB, Gieseke J et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 203:137–144PubMed

American College of Radiology (2003) ACR Breast Imaging-Reporting and Data System (BI-RADS): breast MRI atlas, 4th ed. American College of Radiology, Reston, VA

Sardanelli F, Podo F (2007) Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol 17:873–887PubMedCrossRef

Jansen SA, Newstead GM, Abe H, Shimauchi A, Schmidt RA, Karczmar GS (2007) Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology 245:684–691PubMedCrossRef

Teifke A, Lehr H, Vomweg T, Hlawatsch A, Thelen M (2003) Outcome analysis and rational management of enhancing lesions incidentally detected on contrast-enhanced MRI of the breast. AJR Am J Roentgenol 181:655–662PubMed

Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA (2011) Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol 196:218–224PubMedCrossRef

Baltzer PA, Dietzel M, Vag T et al (2011) Clinical MR mammography: impact of hormonal status on background enhancement and diagnostic accuracy. Rofo 183:441–447PubMedCrossRef

Uematsu T, Kasami M, Watanabe J (2011) Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer? Eur Radiol 21:2261–2267PubMedCrossRef

10.

Pfleiderer SOR, Sachse S, Sauner D (2004) Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res 6:R232–238PubMedCrossRef

11.

Jansen SA, Lin VC, Giger ML, Li H, Karczmar GS, Newstead GM (2011) Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol 21:1374–1382PubMedCrossRef

12.

Chan S, Su M-YL, Lei F-J et al (2011) Menstrual cycle-related fluctuations in breast density measured by using three-dimensional MR imaging. Radiology 261:744–751PubMedCrossRef

13.

Hussain Z, Roberts N, Whitehouse GH, García-Fiñana M, Percy D (1999) Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. Br J Radiol 72:236–245PubMed

14.

Graham SJ, Stanchev PL, Lloyd-Smith JO, Bronskill MJ, Plewes DB (1995) Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 5:695–701PubMedCrossRef

15.

Dean KI, Majurin ML, Komu M (1994) Relaxation times of normal breast tissues. Changes with age and variations during the menstrual cycle. Acta Radiol 35:258–261PubMed

16.

O’Flynn EAM, Morgan VA, Giles SL, Desouza NM (2012) Diffusion weighted imaging of the normal breast: reproducibility of apparent diffusion coefficient measurements and variation with menstrual cycle and menopausal status. Eur Radiol 22(7):1512–1518

17.

Müller-Schimpfle M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203:145–149PubMed

18.

Delille J-P, Slanetz PJ, Yeh ED, Kopans DB, Garrido L (2005) Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J 11:236–241PubMedCrossRef

19.

Rieber A, Nüssle K, Merkle E, Kreienberg R, Tomczak R, Brambs HJ (1999) MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease. Eur Radiol 9:1107–1112PubMedCrossRef

20.

Boyd NF, Melnichouk O, Martin LJ et al (2011) Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol 29:2985–2992PubMedCrossRef

21.

Reichenbach JR, Przetak C, Klinger G, Kaiser WA (1999) Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 23:407–413PubMedCrossRef

22.

Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging—initial observations. Radiology 235:36–41PubMedCrossRef

23.

Völzke H, Alte D, Schmidt CO et al (2011) Cohort profile: the study of health in Pomerania. Int J Epidemiol 40:294–307PubMedCrossRef

24.

Hegenscheid K, Kühn JP, Volzke H, Biffar R, Hosten N, Puls R (2009) Whole-body magnetic resonance imaging of healthy volunteers: pilot study results from the population-based SHIP study. Rofo 181:748–759PubMedCrossRef

25.

Kaiser WA, Zeitler E (1989) MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681–686PubMed

26.

Snijders T, Bosker R (1999) Multilevel analysis: an introduction to basic and advances multilevelmodeling. Sage Publications, London

27.

Hulka CA, Smith BL, Sgroi DC et al (1995) Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 197:33–38PubMed

28.

Hulka CA, Edmister WB, Smith BL (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837–842PubMed

29.

Zeppa R (1969) Vascular response of the breast to estrogen. J Clin Endocrinol Metab 29:695–700PubMedCrossRef

30.

Potten CS, Watson RJ, Williams GT et al (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163–170PubMedCrossRef

31.

Teifke A, Hlawatsch A, Beier T et al (2002) Undetected malignancies of the breast: dynamic contrast-enhanced MR imaging at 1.0 T. Radiology 224:881–888PubMedCrossRef

32.

Neubauer H, Li M, Kuehne-Heid R, Schneider A, Kaiser WA (2003) High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol 76:3–12PubMedCrossRef

33.

Marklund M, Christensen R, Torp-Pedersen S, Thomsen C, Nolsøe CP (2009) Signal intensity of normal breast tissue at MR mammography on midfield: applying a random coefficient model evaluating the effect of doubling the contrast dose. Eur J Radiol 69:93–101PubMedCrossRef

34.

Kulier R, Helmerhorst FM, Maitra N, Gülmezoglu AM (2004) Effectiveness and acceptability of progestogens in combined oral contraceptives—a systematic review. Reprod Health 1:1PubMedCrossRef

35.

Fujimoto J, Sakaguchi H, Hirose R, Tamaya T (1998) Sex steroidal regulation of vessel permeability associated with vessel endothelial cadherin (V-cadherin). J Steroid Biochem Mol Biol 67:25–32PubMedCrossRef

36.

Wang J, Jiang C, Li X, Liu C, Cheng N, Hao Y (2009) The protective mechanism of progesterone on blood-brain barrier in cerebral ischemia in rats. Brain Res Bull 79:426–430PubMedCrossRef

Title: Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy
Authors: Katrin Hegenscheid
Carsten O. Schmidt
Rebecca Seipel
René Laqua
Ralf Ohlinger
Norbert Hosten
Ralf Puls
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: European Radiology / Issue 12/2012
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-012-2544-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 12/2012

Quantitative pulmonary perfusion imaging at 3.0 T of 2-year-old children after congenital diaphragmatic hernia repair: initial results

Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review

Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies

Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?

Diagnostic performance of coronary CT angiography for stenosis detection according to calcium score: systematic review and meta-analysis

Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography